Forward-Looking Statements
This Current Report on Form8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the Company’s estimated cash, cash equivalents and short-term investments as of December 31, 2019; the Company’s belief that its cash, cash equivalents and short-term investments as of December 31, 2019 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2021; and the Company’s plans to report data in the third quarter of 2020 from the Phase 1/2 clinical trial of MRT5005. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: the Company’s ability to advance the development of its platform and programs under the timelines it projects, demonstrate the requisite safety and efficacy of its product candidates and replicate in clinical trials any positive findings from preclinical studies; the content and timing of decisions made by the U.S. Food and Drug Administration, other regulatory authorities and investigational review boards at clinical trial sites, including as it relates to ongoing and planned clinical trials; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the availability of significant cash required to fund operations; competitive factors; general economic and market conditions and other important risk factors discussed in the “Risk Factors” section in the Company’s Quarterly Report on Form10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission (“SEC”) on November 6, 2019, and in any other subsequent filings made by the Company with the SEC. Any forward-looking statements contained in this Current Report on Form8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Item 2.02 Results of Operations and Financial Condition.
The information provided in Item 8.01 of this Current Report onForm 8-K regarding the Company’s estimated cash, cash equivalents and short-term investments as of December 31, 2019 and its ability to fund its operating expenses and capital expenditure requirements is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
Translate Bio, Inc. (the “Company”) from time to time presents or distributes to the investment community, at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of the Company’s current corporate slide presentation is attached to this Current Reporton Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
